News
The REV102 program originated from a joint venture between Rallybio and Recursion focused on the discovery and development of novel, orally available small molecule inhibitors of ENPP1 for the ...
The REV102 program originated from a joint venture between Rallybio and Recursion focused on the discovery and development of novel, orally available small molecule inhibitors of ENPP1 for the ...
In addition, Rallybio may be eligible to receive certain payments in the event of Recursion’s sale of the REV102 program.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback